Giving in Numbers (TM): 2025 Edition - Companies Aligning Business Practices with Purpose Report 25% Higher Revenue and 22% Higher Pre-Tax Profit

NEW YORK CITY, NY / ACCESS Newswire / October 16, 2025 / Despite an ever-changing operating environment, companies that align ...

TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care

Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-3 study. The study evaluates the ...